Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection

Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection

Abstract Pulmonary hypertension (PH) complicates the treatment of interstitial lung disease (ILD) patients resulting in poor functional status and worse outcomes. Early recognition of PH in ILD is important for initiating therapy and considering lung transplantation. However, no standard exists rega...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Raj Parikh, Ippokratis Konstantinidis, David M. O'Sullivan, Harrison W. Farber
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	Wiley 2022-10-01
Sraith:	Pulmonary Circulation
Ábhair:	idiopathic pulmonary fibrosis interstitial lung disease prostacyclin pulmonary hypertension treprostinil
Rochtain ar líne:	https://doi.org/10.1002/pul2.12141

Míreanna comhchosúla

The PH‐ILD Detection tool: External validation and use in patients with ILD
de réir: Raj Parikh, et al.
Foilsithe / Cruthaithe: (2023-07-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
de réir: Julia McSweeney, et al.
Foilsithe / Cruthaithe: (2023-04-01)

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil
de réir: Aparna C. Swaminathan, et al.
Foilsithe / Cruthaithe: (2024-11-01)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
de réir: Jenna M. Faircloth, et al.
Foilsithe / Cruthaithe: (2023-03-01)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
de réir: Jenna M. Faircloth, et al.
Foilsithe / Cruthaithe: (2023-08-01)

The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil
de réir: Piotr Kędzierski, et al.
Foilsithe / Cruthaithe: (2025-01-01)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
de réir: Abdullah A. Alqarni, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
de réir: Shelsey W. Johnson, et al.
Foilsithe / Cruthaithe: (2022-07-01)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
de réir: Nicholas S. Hill, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future
de réir: Ahmad Arslan, et al.
Foilsithe / Cruthaithe: (2024-01-01)

PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis
de réir: Ning Zhao, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia
de réir: Maria S. Nashatyreva, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension
de réir: Garance Kopp, et al.
Foilsithe / Cruthaithe: (2020-10-01)

Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
de réir: Kellie Morland, et al.
Foilsithe / Cruthaithe: (2021-10-01)

Interstitial Lung Abnormality in Asian Population
de réir: Gong Yong Jin
Foilsithe / Cruthaithe: (2024-04-01)

The application of metabolomics toward idiopathic pulmonary fibrosis and potential metabolomic value of diverse samples in interstitial lung diseases
de réir: Mingtao Liu, et al.
Foilsithe / Cruthaithe: (2023-09-01)

CLINICAL PROFILE OF INTERSTITIAL LUNG DISEASES CASES
de réir: Gagiya Ashok K, et al.
Foilsithe / Cruthaithe: (2012-03-01)

Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease
de réir: Alexandra Lawrence, et al.
Foilsithe / Cruthaithe: (2024-09-01)

Pulmonary Hypertension in Interstitial Lung Disease: Updates in Disease, Diagnosis, and Therapeutics
de réir: Zachary A. Haynes, et al.
Foilsithe / Cruthaithe: (2023-10-01)

Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
de réir: E. A. Rezukhina, et al.
Foilsithe / Cruthaithe: (2021-09-01)

Interstitial lung diseases with progressive pulmonary fibrosis: pathogenetic features and approaches to therapy
de réir: N. A. Kuzubova, et al.
Foilsithe / Cruthaithe: (2020-11-01)

Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date
de réir: Cassady SJ, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Osteopontin as a Biomarker in Interstitial Lung Diseases
de réir: David Iturbe-Fernández, et al.
Foilsithe / Cruthaithe: (2024-05-01)

Multidisciplinary discussion for diagnosis of interstitial lung disease in real life
de réir: Sabina Anna Guler, et al.
Foilsithe / Cruthaithe: (2016-05-01)

Increased expiratory flows identify early interstitial lung disease
de réir: Sami Mohammed Alyami, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Role of Telomere Length in Survival of Patients with Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
de réir: Sofía Tesolato, et al.
Foilsithe / Cruthaithe: (2023-12-01)

Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
de réir: Jonathan Keow, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Evaluation of progressive pulmonary fibrosis in non-idiopathic pulmonary fibrosis-interstitial lung diseases: a cross-sectional study
de réir: Özlem Erçen Diken, et al.
Foilsithe / Cruthaithe: (2024-08-01)

Estimation of plasmic concentration of the brain natriuretic peptide in interstitial pulmonary diseases with pulmonary hypertension: clinical role
de réir: N A Mukhin, et al.
Foilsithe / Cruthaithe: (2009-03-01)

Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis
de réir: Lianghua Xiao, et al.
Foilsithe / Cruthaithe: (2024-09-01)

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
de réir: Justin M. Oldham, et al.
Foilsithe / Cruthaithe: (2017-08-01)

Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis
de réir: Pierson Richard, et al.
Foilsithe / Cruthaithe: (2002-02-01)

Abnormal platelet aggregation in pediatric pulmonary hypertension
de réir: Stephanie S. Handler, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis
de réir: Avignat S. Patel, et al.
Foilsithe / Cruthaithe: (2023-02-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
de réir: Jia Liu, et al.
Foilsithe / Cruthaithe: (2024-04-01)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
de réir: Hardin EA, et al.
Foilsithe / Cruthaithe: (2016-11-01)

A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost
de réir: Ji Hoon Jang, et al.
Foilsithe / Cruthaithe: (2024-08-01)

An observational cohort study of interstitial lung abnormalities (ILAs) in a large Japanese health screening population (Kumamoto ILA study in Japan: KILA-J)
de réir: Kazuya Ichikado, et al.
Foilsithe / Cruthaithe: (2023-06-01)

Noninvasive determinants of pulmonary hypertension in interstitial lung disease
de réir: Phillip Joseph, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Severe bronchospasm and acute respiratory failure associated with inhaled prostacyclin therapy
de réir: Donna Steinbacher, et al.
Foilsithe / Cruthaithe: (2024-04-01)